Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi.
<h4>Background</h4>The Ministry of Health in Malawi is implementing a pragmatic and innovative approach for the management of all HIV-infected pregnant women, termed Option B+, which consists of providing life-long antiretroviral treatment, regardless of their CD4 count or clinical stage...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c9e8c0b1c2e543729cee0ef3fb188a65 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c9e8c0b1c2e543729cee0ef3fb188a65 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c9e8c0b1c2e543729cee0ef3fb188a652021-11-18T07:53:52ZCost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi.1932-620310.1371/journal.pone.0057778https://doaj.org/article/c9e8c0b1c2e543729cee0ef3fb188a652013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23554867/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The Ministry of Health in Malawi is implementing a pragmatic and innovative approach for the management of all HIV-infected pregnant women, termed Option B+, which consists of providing life-long antiretroviral treatment, regardless of their CD4 count or clinical stage. Our objective was to determine if Option B+ represents a cost-effective option.<h4>Methods</h4>A decision model simulates the disease progression of a cohort of HIV-infected pregnant women receiving prophylaxis and antiretroviral therapy, and estimates the number of paediatric infections averted and maternal life years gained over a ten-year time horizon. We assess the cost-effectiveness from the Ministry of Health perspective while taking into account the practical realities of implementing ART services in Malawi.<h4>Results</h4>If implemented as recommended by the World Health Organization, options A, B and B+ are equivalent in preventing new infant infections, yielding cost effectiveness ratios between US$ 37 and US$ 69 per disability adjusted life year averted in children. However, when the three options are compared to the current practice, the provision of antiretroviral therapy to all mothers (Option B+) not only prevents infant infections, but also improves the ten-year survival in mothers more than four-fold. This translates into saving more than 250,000 maternal life years, as compared to mothers receiving only Option A or B, with savings of 153,000 and 172,000 life years respectively. Option B+ also yields favourable incremental cost effectiveness ratios (ICER) of US$ 455 per life year gained over the current practice.<h4>Conclusion</h4>In Malawi, Option B+ represents a favorable policy option from a cost-effectiveness perspective to prevent future infant infections, save mothers' lives and reduce orphanhood. Although Option B+ would require more financial resources initially, it would save societal resources in the long-term and represents a strategic option to simplify and integrate HIV services into maternal, newborn and child health programmes.Olufunke FasaweCarlos AvilaNathan ShafferErik SchoutenFrank ChimbwandiraDavid HoosOlive NakakeetoPaul De LayPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e57778 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Olufunke Fasawe Carlos Avila Nathan Shaffer Erik Schouten Frank Chimbwandira David Hoos Olive Nakakeeto Paul De Lay Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. |
| description |
<h4>Background</h4>The Ministry of Health in Malawi is implementing a pragmatic and innovative approach for the management of all HIV-infected pregnant women, termed Option B+, which consists of providing life-long antiretroviral treatment, regardless of their CD4 count or clinical stage. Our objective was to determine if Option B+ represents a cost-effective option.<h4>Methods</h4>A decision model simulates the disease progression of a cohort of HIV-infected pregnant women receiving prophylaxis and antiretroviral therapy, and estimates the number of paediatric infections averted and maternal life years gained over a ten-year time horizon. We assess the cost-effectiveness from the Ministry of Health perspective while taking into account the practical realities of implementing ART services in Malawi.<h4>Results</h4>If implemented as recommended by the World Health Organization, options A, B and B+ are equivalent in preventing new infant infections, yielding cost effectiveness ratios between US$ 37 and US$ 69 per disability adjusted life year averted in children. However, when the three options are compared to the current practice, the provision of antiretroviral therapy to all mothers (Option B+) not only prevents infant infections, but also improves the ten-year survival in mothers more than four-fold. This translates into saving more than 250,000 maternal life years, as compared to mothers receiving only Option A or B, with savings of 153,000 and 172,000 life years respectively. Option B+ also yields favourable incremental cost effectiveness ratios (ICER) of US$ 455 per life year gained over the current practice.<h4>Conclusion</h4>In Malawi, Option B+ represents a favorable policy option from a cost-effectiveness perspective to prevent future infant infections, save mothers' lives and reduce orphanhood. Although Option B+ would require more financial resources initially, it would save societal resources in the long-term and represents a strategic option to simplify and integrate HIV services into maternal, newborn and child health programmes. |
| format |
article |
| author |
Olufunke Fasawe Carlos Avila Nathan Shaffer Erik Schouten Frank Chimbwandira David Hoos Olive Nakakeeto Paul De Lay |
| author_facet |
Olufunke Fasawe Carlos Avila Nathan Shaffer Erik Schouten Frank Chimbwandira David Hoos Olive Nakakeeto Paul De Lay |
| author_sort |
Olufunke Fasawe |
| title |
Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. |
| title_short |
Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. |
| title_full |
Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. |
| title_fullStr |
Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. |
| title_full_unstemmed |
Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. |
| title_sort |
cost-effectiveness analysis of option b+ for hiv prevention and treatment of mothers and children in malawi. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/c9e8c0b1c2e543729cee0ef3fb188a65 |
| work_keys_str_mv |
AT olufunkefasawe costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT carlosavila costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT nathanshaffer costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT erikschouten costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT frankchimbwandira costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT davidhoos costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT olivenakakeeto costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi AT pauldelay costeffectivenessanalysisofoptionbforhivpreventionandtreatmentofmothersandchildreninmalawi |
| _version_ |
1718422795577196544 |